|
|||
DRUGS & SUPPLEMENTS
|
What are the side effects you encounter while taking this medicine? |
Cromolyn Sodium:
Intal Compound (Cromolyn Sodium)
Drug Facts
Intal Compound (Cromolyn Sodium) sodium 5.2mg
Nasal allergy symptom controller
to prevent and relieve nasal symptoms of hay fever and other nasal allergies:
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
benzalkonium chloride, edetate disodium, purified water
call 1-877-9-ALLERGY (1-877-925-5374)
Isoproterenol Sulfate:
Intal Compound (Isoproterenol Sulfate) hydrochloride injection is indicated:
Use of Intal Compound (Isoproterenol Sulfate) hydrochloride injection is contraindicated in patients with tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; and angina pectoris.
Intal Compound (Isoproterenol Sulfate) hydrochloride injection, by increasing myocardial oxygen requirements while decreasing effective coronary perfusion, may have a deleterious effect on the injured or failing heart. Most experts discourage its use as the initial agent in treating cardiogenic shock following myocardial infarction. However, when a low arterial pressure has been elevated by other means, Intal Compound (Isoproterenol Sulfate) hydrochloride injection may produce beneficial hemodynamic and metabolic effects.
In a few patients, presumably with organic disease of the AV node and its branches, Intal Compound (Isoproterenol Sulfate) hydrochloride injection has paradoxically been reported to worsen heart block or to precipitate Adams-Stokes attacks during normal sinus rhythm or transient heart block.
Intal Compound hydrochloride injection should generally be started at the lowest recommended dose. This may be gradually increased if necessary while carefully monitoring the patient. Doses sufficient to increase the heart rate to more than 130 beats per minute may increase the likelihood of inducing ventricular arrhythmias. Such increases in heart rate will also tend to increase cardiac work and oxygen requirements which may adversely affect the failing heart or the heart with a significant degree of arteriosclerosis.
Adequate filling of the intravascular compartment by suitable volume expanders is of primary importance in most cases of shock and should precede the administration of vasoactive drugs. In patients with normal cardiac function, determination of central venous pressure is a reliable guide during volume replacement. If evidence of hypoperfusion persists after adequate volume replacement, Intal Compound (Isoproterenol Sulfate) hydrochloride injection may be given.
In addition to the routine monitoring of systemic blood pressure, heart rate, urine flow, and the electrocardiograph, monitor the response to therapy by frequent determination of the central venous pressure and blood gases. Closely observe patients in shock during Intal Compound (Isoproterenol Sulfate) hydrochloride injection administration. If the heart rate exceeds 110 beats per minute, it may be advisable to decrease the infusion rate or temporarily discontinue the infusion. Determinations of cardiac output and circulation time may also be helpful. Take appropriate measures to ensure adequate ventilation. Pay attention to acid-base balance and to the correction of electrolyte disturbances.
Intal Compound (Isoproterenol Sulfate) hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias. The drugs may, however, be administered alternately provided a proper interval has elapsed between doses.
Avoid Intal Compound (Isoproterenol Sulfate) when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
Long-term studies in animals to evaluate the carcinogenic potential of Intal Compound hydrochloride have not been done. Mutagenic potential and effect on fertility have not been determined. There is no evidence from human experience that Intal Compound (Isoproterenol Sulfate) hydrochloride injection may be carcinogenic or mutagenic or that it impairs fertility.
Animal reproduction studies have not been conducted with Intal Compound (Isoproterenol Sulfate) hydrochloride. It is also not known whether Intal Compound (Isoproterenol Sulfate) hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Intal Compound (Isoproterenol Sulfate) hydrochloride should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Intal Compound hydrochloride injection is administered to a nursing woman.
Safety and efficacy of Intal Compound (Isoproterenol Sulfate) in pediatric patients have not been established.
Intravenous infusions of Intal Compound (Isoproterenol Sulfate) in refractory asthmatic children at rates of 0.05-2.7 mcg/kg/min have caused clinical deterioration, myocardial necrosis, congestive heart failure and death. The risks of cardiac toxicity appear to be increased by some factors [acidosis, hypoxemia, coadministration of corticosteroids, coadministration of methylxanthines (theophylline, theobromine) or aminophylline] that are especially likely to be present in these patients. If I.V. Intal Compound (Isoproterenol Sulfate) is used in children with refractory asthma, patient monitoring must include continuous assessment of vital signs, frequent electrocardiography, and daily measurements of cardiac enzymes, including CPK-MB.
Clinical studies of Intal Compound (Isoproterenol Sulfate) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects in clinical circumstances. There are, however, some data that suggest that elderly healthy or hypertensive patients are less responsive to beta-adrenergic stimulation than are younger subjects. In general, dose selection for elderly patients should usually start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.
The following reactions to Intal Compound (Isoproterenol Sulfate) hydrochloride injection have been reported:
CNS: Nervousness, headache, dizziness, nausea, visual blurring.
Cardiovascular: Tachycardia, palpitations, angina, Adams-Stokes attacks, pulmonary edema, hypertension, hypotension, ventricular arrhythmias, tachyarrhythmias.
In a few patients, presumably with organic disease of the AV node and its branches, Intal Compound (Isoproterenol Sulfate) hydrochloride injection has been reported to precipitate Adams-Stokes seizures during normal sinus rhythm or transient heart block.
Respiratory: Dyspnea.
Other: Flushing of the skin, sweating, mild tremors, weakness, pallor.
To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The acute toxicity of Intal Compound (Isoproterenol Sulfate) hydrochloride in animals is much less than that of epinephrine. Excessive doses in animals or man can cause a striking drop in blood pressure, and repeated large doses in animals may result in cardiac enlargement and focal myocarditis.
In case of accidental overdosage as evidenced mainly by tachycardia or other arrhythmias, palpitations, angina, hypotension, or hypertension, reduce rate of administration or discontinue Intal Compound (Isoproterenol Sulfate) hydrochloride injection until patient’s condition stabilizes. Blood pressure, pulse, respiration, and ECG should be monitored.
It is not known whether Intal Compound (Isoproterenol Sulfate) hydrochloride is dialyzable.
The oral LD50 of Intal Compound (Isoproterenol Sulfate) hydrochloride in mice is 3,850 mg/kg ± 1,190 mg/kg of pure drug in solution.
Start Intal Compound (Isoproterenol Sulfate) injection at the lowest recommended dose and increase the rate of administration gradually if necessary while carefully monitoring the patient. The usual route of administration is by intravenous infusion or bolus intravenous injection. In dire emergencies, the drug may be administered by intracardiac injection. If time is not of the utmost importance, initial therapy by intramuscular or subcutaneous injection is preferred.
Route of Administration | Preparation of Dilution | Initial Dose | Subsequent Dose Range |
Bolus intravenous injection | Dilute 1 mL (0.2 mg) in 9 mL of Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP | 0.02 mg to 0.06 mg (1 mL to 3 mL of diluted solution) | 0.01mg to 0.2 mg (0.5 mL to 10 mL of diluted solution) |
Intravenous infusion | Dilute 10 mL (2 mg) in 500 mL of 5% Dextrose Injection, USP | 5 mcg/min. (1.25 mL of diluted solution per minute) | |
Intramuscular | Use Solution undiluted | 0.2 mg (1 mL) | 0.02 mg to 1 mg (0.1 mL to 5 mL) |
Subcutaneous | Use Solution undiluted | 0.2 mg (1 mL) | 0.15 mg to 0.2 mg (0.75 mL to 1 mL) |
Intracardiac | Use Solution undiluted | 0.02 mg (0.1 mL) |
There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min.
Route of Administration | Preparation of Dilution | Infusion Rate |
Intravenous infusion | Dilute 5 mL (1 mg) in 500 mL of 5% Dextrose Injection, USP | 0.5 mcg to 5 mcg per minute (0.25 mL to 2.5 mL of diluted solution) |
Recommended dosage for adults with bronchospasm occurring during anesthesia:
Route of Administration | Preparation of Dilution | Initial Dose | Subsequent Dose |
Bolus intravenous injection | Dilute 1 mL (0.2 mg) in 9 mL of Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP | 0.01 mg to 0.02 mg (0.5 mL to 1 mL of diluted solution) | The initial dose may be repeated when necessary |
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Such solution should not be used.
NDC Number | Container | Concentration | Fill | Quantity |
0187-4330-01 | Ampul | 0.2 mg/mL | 1 mL | UNI-AMP pak of 25 |
0187-4330-05 | Ampul | 1 mg/5 mL (0.2 mg/mL) | 5 mL | 10 ampuls per carton |
Protect from light. Keep in opaque container until used.
Store at 20° to 25°C (68° to 77°F).
Do not use if the injection is pinkish or darker than slightly yellow or contains a precipitate.
Manufactured for:
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
Manufactured by:
Hospira, Inc.
McPherson, KS 67460 USA
9445502
Rev. 08/2016
Intal Compound (Isoproterenol Sulfate) is a registered trademark of Hospira, Inc. used under license.
©Valeant Pharmaceuticals North America LLC
5 mL
NDC 0187-4330-05
Rx only
Isuprel®
Intal Compound (Isoproterenol Sulfate) HC1
Injection, USP
1 mg/5 mL (0.2 mg/mL)
Intravenous, Subcutaneous,
Intramuscular or Intracardiac Use Only.
Protect from light.
Manufactured for:
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
©Valeant Pharmaceuticals North America LLC
Depending on the reaction of the Intal Compound after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Intal Compound not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Intal Compound addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Visitors | % | ||
---|---|---|---|
Twice in a day | 1 | 100.0% |
Visitors | % | ||
---|---|---|---|
> 60 | 1 | 100.0% |
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology